PDL BioPharma Inc

PDL BioPharma — Jefferies 2017 Global Healthcare Conference

53 slides from PDL BioPharma's conference presentation, Jun 7, 2017

  1. Slide 1: Jefferies 2017 Global Healthcare Conference

    Slide 1: Jefferies 2017 Global Healthcare Conference

    PDL Jefferies 2017 Global Healthcare Conference June 9, 2017

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements, including PDL’s expectations with respect to its future revenues, expenses, net income and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actual result

  3. Slide 3: PDL at a Glance

    Slide 3: PDL at a Glance

    PDL at a Glance PDL BioPharma seeks to provide a significant return for its shareholders by i and managing a portfolio of companies, products, royalty agreements and ies in the biotech, pharmaceutical and medical device industries. CURRENT EQUITY INVESTMENTS: lo Noden Pharma DAC, an Irish domiciled

  4. Slide 4: PDL Future: Focus on Growth Opportunities

    Slide 4: PDL Future: Focus on Growth Opportunities

    PDL Future: Focus on Growth Opportunities Specialty Pharma Q Diversification via acquisition of additional specialty pharma products and companies with a focus on under commercialized products. QO Noden expands, commercializing products in U.S and in key markets in the rest of world. QO Use proceeds

  5. Slide 5: Key Information and Facts

    Slide 5: Key Information and Facts

    Key Information and Facts Ticker PDLI (NASDAQ) Location Incline Village, Nevada Share Price $2.45 Book Value $4.63 per share Current Deployed on Royalty Investments $396 million Current Deployed on Debt Investments $220 million Current Deployed on Equity Investments — $107 million Cash Deployed on C

  6. Slide 6: Building Value Through Investments

    Slide 6: Building Value Through Investments

    Building Value Through Investments PDL’s book value has increased 18 fold in the past 3 % years. Total Assets currently exceed $1.2 billion. PDL's Book Value Per Share $5.00 $4.75 $4.50 $4.25 $4.00 $3.75 $3.50 $3.25 $3.00 $2.75 $2.50 $2.25 $2.00 $1.75 $1.50 $1.25 $1.00 $0.75 $0.50 $0.25 $0.00 oe — D

  7. Slide 7: Experienced Leadership

    Slide 7: Experienced Leadership

    Experienced Leadership Management John McLaughlin President & CEO Christopher Stone VP, General Counsel & Secretary Peter Garcia VP & Chief Financial Officer Danny Hart VP, Business Development Steffen Pietzke VP, Finance & Chief Accounting Officer Nathan Kryszak Deputy General Counsel & Assistant S

  8. Slide 8: Noden Pharma

    Slide 8: Noden Pharma

    PDL NODEN y PHARMA

  9. Slide 9: Noden Current Product Portfolio

    Slide 9: Noden Current Product Portfolio

    Noden Current Product Portfolio Product Therapeutic & Geographic Area Olan Ofekhenacc Hypertension - U.S. | Ph eort 5 i - soem. Hypertension - Rest of World = : SSS =} — Fe

  10. Slide 10: Tekturna Products in Noden

    Slide 10: Tekturna Products in Noden

    40 Tekturna Products in Noden United States o Tekturna®- aliskiren is a direct renin inhibitor for the treatment of hypertension that reduces plasma renin by inhibiting the conversion of angiotensinogen to angiotensin I. = Not for use with ACEs or ARBs in patients with diabetes or renal impairment a

  11. Slide 11: Tekturna Market: Hypertension

    Slide 11: Tekturna Market: Hypertension

    Tekturna Market: Hypertension o Chronic condition with serious long-term cardiovascular implications which affects about 29% of the U.S. adult population. = 78 million in U.S. alone. o Majority of hypertension diagnosis and management occurs in primary care setting (PCP) with rare referrals when the

  12. Slide 12: Tekturna Products Labeling

    Slide 12: Tekturna Products Labeling

    Tekturna Products Labeling For full prescribing information for Tekturna and Tekturna HCT, please visit: www.tekturna.com. © Freee ion O (aliskiren and Hntnhiotade) (oles 190 mg/12.5 mg + 150.mg/25 mg + 300 mg/T2.5 mg + 300mg/25mg PDL

  13. Slide 13: Tekturna: Safety Profile

    Slide 13: Tekturna: Safety Profile

    8 Tekturna: Safety Profile o Safety data in more than 6,460 patients, including 1,740 treated for longer than 6 months and more than 1,250 treated for longer than 1 year. o Discontinuation of therapy due to clinical adverse event occurred in 2.2% of Tekturna treated patients compared to 3.5% of plac

  14. Slide 14: Tekturna: Safety Profile

    Slide 14: Tekturna: Safety Profile

    14 Tekturna: Safety Profile Placebo-Controlled Trials Tekturna () Adverse Event Selected AE’s in Patients with Type 2 Kidney Disease, Diabetes and Chro' CV Disease, or Both Edema 04 05 Diarrhea oS 42 Cough 14 06 Rash 40 03 Elevated Uric Acid 04 04 Gout 02 0.4 Renal Stones 02 0.0 Adverse Event Renal

  15. Slide 15: Tekturna: Market Research

    Slide 15: Tekturna: Market Research

    15 Tekturna: Market Research o Novartis = No active sales or marketing efforts with respect to Tekturna products for last 4 years. o Market Research = 21 in-depth qualitative interviews with PCPs, cardiologists, hypertension specialists, and payers. = 209 participated in quantitative survey of PCPs,

  16. Slide 16: Noden Pharma Entities

    Slide 16: Noden Pharma Entities

    16 Noden Pharma Entities o Noden DAC = Domiciled in Ireland. = Expected to be a tax efficient structure. « Responsible for development and commercialization activities worldwide. « Responsible for bulk tablet manufacture worldwide and fill-and-finish ex-US. o NodenUSA = Domiciled in Delaware. = Resp

  17. Slide 17: Product Transition from Novartis

    Slide 17: Product Transition from Novartis

    v7 Product Transition from Novartis Commercialization o US = Novartis initially distributed product and Noden receiving a transfer of profit. = Noden USA assumed commercialization responsibilities on October 5, 2016. = Noden USA fielded a dedicated contract sales force of ~40 reps and 4 district man

  18. Slide 18: Tekturna & Tekturna HCT 2017 U.S. Gross Monthly Revenue

    Slide 18: Tekturna & Tekturna HCT 2017 U.S. Gross Monthly Revenue

    18 Tekturna & Tekturna HCT 2017 U.S. Gross Monthly Revenue $in millions $7.600 $7,425 $7.400 $7,193 $7.200 $7.000 $6,943 $6.800 rey $6.565 $6.442 $6.400 $6.200 $6.000 $5.800 Jan-17 Feb-17 Mar-17 Apr-17 May-17

  19. Slide 19: Noden Team

    Slide 19: Noden Team

    19 Noden Team o InterimCEO = Alan Markey - Eavions! Managing Director of Baxter Healthcare Limited (Ireland), Assistant VP for nbrel - o Head of Sales and Marketing US = Michael McCann — Previously head of US Cardiovascular at Sanofi Genzyme, VP of Global Strategic Marketing for Cardiovascular. o He

  20. Slide 20: Novartis/Tekturna Deal

    Slide 20: Novartis/Tekturna Deal

    20 Novartis/Tekturna Deal o Total Tekturna Potential Purchase Price » Up to $334 million. o Closing Payments » $110 million paid to Novartis in July 2016. o First Anniversary = $89 million due to Novartis in July 2017. o Milestones » Up to $95 million based on sales levels and generic competition. o

  21. Slide 21: Tekturna Intellectual Property

    Slide 21: Tekturna Intellectual Property

    21 Tekturna Intellectual Property Tekturna is protected by multiple patents covering composition of matter, pharmaceutical formulation and methods of manufacture. o United States = Composition of matter protection to 2018 for Tekturna; listed in the Orange Book; possible extension for 6 months with

  22. Slide 22: Business Updates

    Slide 22: Business Updates

    PDL Business Updates

  23. Slide 23: LENSAR - a wholly owned subsidiary of PDL

    Slide 23: LENSAR - a wholly owned subsidiary of PDL

    LENSAR - a wholly owned subsidiary of PDL o On May 11, LENSAR and PDL announced the financial restructuring of LENSAR = LENSAR is now a wholly owned subsidiary of PDL = Most of LENSAR outstanding debt owed to PDL was converted to equity = PDL will consolidate LENSAR’s financial statements effective

  24. Slide 24: LENSAR

    Slide 24: LENSAR

    | LENSAR LENSAR, Inc. is a_ leading global developer and manufacturer of Femtosecond Cataract Lasers (FLS) in the growing cataract surgery market. Cataract surgery is the highest volume surgical procedure globally. — Market penetration of FLS approx. 7% of total procedures in U.S. while < 2% OUS. —

  25. Slide 25: LENSAR Highlights

    Slide 25: LENSAR Highlights

    LENSAR Highlights Leading Technology Platform Positioned For Growth Cataract surgery is the highest volume surgical procedure performed worldwide with over 24.9 million surgeries estimated to be performed in 2016. Integration of preoperative diagnostics into the cataract refractive suite driving the

  26. Slide 26: Keytruda Patent Litigation Settlement

    Slide 26: Keytruda Patent Litigation Settlement

    Keytruda Patent Litigation Settlement o On April 21, 2017, the Company entered into a settlement agreement with Merck to resolve the patent infringement lawsuit between the parties. o PDL granted Merck a fully paid-up, royalty-free, non-exclusive license to certain of the Company’s Queen et al. pate

  27. Slide 27: PDL Share Repurchase Program

    Slide 27: PDL Share Repurchase Program

    27 PDL Share Repurchase Program o InMarch 2017 PDL’s board authorized the repurchase of PDL common stock having an aggregate value of up to $30 million through March 2018. o Stock repurchase program represents an appropriate use of the company's cash and will create shareholder value while maintaini

  28. Slide 28: Investments Overview

    Slide 28: Investments Overview

    PDL Investments Overview

  29. Slide 29: Royalty & Debt Investments

    Slide 29: Royalty & Debt Investments

    16 Royalty & Debt Investments Royalty Acquisition Royalty Acquisition [kybella Royalty Acquisition AicelRx Pharmaceuticals, ino Financing careMiy $9,500,000 $85,000,000 ‘$40,000,000 $85,600,000 $15,500,000 July 2016 September2015 “lune 2045, Novernber2014 “lune 2044 Senior Securediiote | [ Royalty T

  30. Slide 30: Royalty Acquisitions

    Slide 30: Royalty Acquisitions

    Royalty Acquisitions — $496MM Invested Glumetza 3,€Pevomed YYVALEANT indefinite Bagpeaem, — 3yDepomed: §— <emencie, 6/2018 HERELESIOAR — XE Depome (Ge 5/2026 < $240.5M $221.5M > InYoxamet XR = 3Mepepomed —_ yanssen J 9/2023 ‘Stones ress tne mle FAB, BE Devomee GiB Ly, 12/2026 Hague Sno Sno Payoff $1

  31. Slide 31: Concluded Investment Track Record

    Slide 31: Concluded Investment Track Record

    Concluded Investment Track Record Transaction Cash ixCash Cash Return Transaction Total © Amount Received Return (Money —_Pre-Taxed Date Committed Invested byPDL (Years) Multiple) _—_IRR% | Merus Labs Jul-2012 ~_AxoGen! Oct-2012 _Durata, Oct-2013 ~ avinger? Apr-2013 |_Paradigm Spine _Feb-2014 x x |

  32. Slide 32: Financials

    Slide 32: Financials

    PDL Financials

  33. Slide 33: First Quarter 2017 Financials

    Slide 33: First Quarter 2017 Financials

    First Quarter 2017 Financials Three Months Ended March 31, (In thousands, except per share amounts) (unaudited) 2017 2016 Royalties from Queen et al. patents $14,156 _$ 121,455 Royalty rights - change in fair value 13,146 (27,102) Interest revenue 5,457 8,964 Product revenue, net License and other 1

  34. Slide 34: Strong Balance Sheet

    Slide 34: Strong Balance Sheet

    Strong Balance Sheet ($in millions) March 31, 2017 Cash, cash equivalents and investments $409 Total Assets $1,237 Debt: 4.00% Convertible Debt- due February 2018 ($9.17 conversion p/s) 126 2.75% Convertible Debt — due December 2021 ($3.81 conversion p/s) 1 150 Total Debt $276 PDL refinanced a porti

  35. Slide 35: Conclusion

    Slide 35: Conclusion

    PDL Conclusion

  36. Slide 36: Investment Highlights and 2017 Priorities

    Slide 36: Investment Highlights and 2017 Priorities

    Investment Highlights and 2017 Priorities HIGHLIGHTS ekturna and Tekturna HCT are important products for treatment of hypertension with differentiated mechanism of action and potential upside in revenues if promoted INoden investment was immediately cash flow accretive to PDL. iWe have a team with d

  37. Slide 37: Appendix: Additional Details and Updates on Investments

    Slide 37: Appendix: Additional Details and Updates on Investments

    PDL Appendix: Additional Details and Updates on Investments

  38. Slide 38: AcelRx

    Slide 38: AcelRx

    PDL ARIAD Avinger AxoGen CareView Depomed Direct Flow Durata kaléo Kybella Lensar Merus Labs Paradigm Spine U. of Michigan CE) sackcround = This is a royalty transaction for $65 million that was entered into on September 18, 2015. PDL acquired 75% of the royalty that Griinenthal pays to AcelRx for r

  39. Slide 39: ARIAD

    Slide 39: ARIAD

    PDL Concluded AcelRx Q Background = This was a royalty transaction for $100 million in exchange for a 2.5% ARIAD royalty on worldwide sales on Iclusig through July 2015, increasing to Avinger 5% through the end of 2018 and to 6.5% thereafter. There is also a | backup royalty on brigatinib. The durat

  40. Slide 40: Avinger

    Slide 40: Avinger

    PDL Concluded | AcelRx ARIAD xoGen Q Background = This was a debt transaction for $20 million entered into on April 18, 2013. Avinger used the proceeds to support the A CareView Depomed | Direct Flow Durata kaléo Kybella Lensar Merus Labs Paradigm Spine U. of Michigan Viscogliosi Bros. Wellstat Diag

  41. Slide 41: AxoGen

    Slide 41: AxoGen

    PDL Concluded | AcelRx ARIAD Avinger CareView Depomed | Direct Flow Durata kaléo Kybella Lensar Merus Labs | Paradigm Spine | U. of Michigan Viscogliosi Bros. Wellstat Diag. Q Background = This transaction was a hybrid royalty/debt transaction for $20.8 million entered into in October 2012 and secur

  42. Slide 42: CareView

    Slide 42: CareView

    PDL AcelRx ARIAD Avinger AxoGen jcarvion Oa Depomed Direct Flow Durata kaléo Kybella Lensar Merus Labs Paradigm Spine U. of Michigan Viscogliosi Bros. Wellstat Diag. Q Background This is a debt transaction for $20 million that was entered into on June 26, 2015 and was funded on October 5, 2015 upon

  43. Slide 43: Depomed

    Slide 43: Depomed

    PDL AcelRx Q Background = This is a royalty transaction for $240.5 million entered into on October 18, 2013, in which PDL ARIAD acquired the rights to royalties and milestones on five products for type 2 diabetes. = 50% of net sales of Glumetza (extended-release metformin) less GOGS until end of Avi

  44. Slide 44: Direct Flow Medical

    Slide 44: Direct Flow Medical

    PDL AcelRx ARIAD Q Background 5 = This is a debt transaction for a total of $58 million that was entered into Avinger on November 5, 2013. PDL provided tranches of $35 million, AxoGen $15 million, $5 million, $1.5 million, $1.5 million and $1.0 million on November 2013, November 2014, January 2016,

  45. Slide 45: Durata

    Slide 45: Durata

    PDL Concluded AcelRx ARIAD Avinger AxoGen CareView Depomed Direct Flow kaléo Kybella Lensar Merus Labs Q Background = This was a debt transaction for $40 million entered into on October 31, 2013 with $25 million advanced at signing and a second tranche of $15 million advanced on May 27, 2014 upon US

  46. Slide 46: kaléo

    Slide 46: kaléo

    PDL AcelRx ARIAD Avinger AxoGen CareView Depomed Direct Flow Kybella Lensar Merus Labs Paradigm Spine U. of Michigan Viscogliosi Bros. Q Background = This is a debt transaction for $150 million that was entered into on April 1, 2014. These secured notes bear interest at 13% per annum The principal b

  47. Slide 47: Kybella

    Slide 47: Kybella

    PDL AcelRx ARIAD Avinger AxoGen CareView Depomed Direct Flow Durata kaléo Lensar Merus Labs Q Background = This is a royalty transaction for $9.5 million that was entered into on July 8, 2016. There is the potential for additional payments of up to $1 million depending on the attainment of certain p

  48. Slide 48: Lensar

    Slide 48: Lensar

    PDL AcelRx ARIAD Avinger AxoGen CareView Depomed Direct Flow Durata kaléo Kybella Merus Labs Paradigm Spine U. of Michigan Viscogliosi Bros. O Background This was a debt transaction with payment of an initial tranche of $40 million as of the time that the agreement was entered into on October 1, 201

  49. Slide 49: Merus Labs

    Slide 49: Merus Labs

    PDL Concluded AcelRx ARIAD Avinger AxoGen CareView Depomed Direct Flow Durata kaléo Kybella Lensar Q Background = This transaction was a debt facility for $55 million entered into in February 2014 and secured by the assets of Merus Labs. = Merus Labs used the funds to support the commercialization o

  50. Slide 50: Paradigm Spine

    Slide 50: Paradigm Spine

    PDL Concluded AcelRx ARIAD Avinger AxoGen CareView Depomed Direct Flow Durata kaléo Kybella Lensar Merus Labs Paradigm Spine Q Background = This was a debt transaction entered into on February 14, 2014 with $50 million advanced as of signing and an additional $4 million under a modification of the o

  51. Slide 51: University of Michigan

    Slide 51: University of Michigan

    PDL AcelRx ARIAD Avinger AxoGen CareView Depomed Direct Flow Durata kaléo Kybella Lensar Merus Labs Paradigm Spine Viscogliosi Bros. Wellstat Diag. Q Background This is a royalty transaction for $65.6 million that was entered into on November 6, 2014. PDL acquired 75% of the royalties due to the Uni

  52. Slide 52: PDL On-Going

    Slide 52: PDL On-Going

    PDL On-Going AcelRx ARIAD Avinger AxoGen CareView Depomed Direct Flow Durata kaléo Kybella Lensar Merus Labs Paradigm Spine U. of Michigan Viscogliosi Bros. Wellstat Diag. PD L

  53. Slide 53: Wellstat Diagnostics

    Slide 53: Wellstat Diagnostics

    PDL AcelRx ARIAD Avinger AxoGen CareView Depomed Direct Flow Durata kaléo Kybella Lensar Merus Labs Paradigm Spine U. of Michigan Wellstat Diag. Viscogliosi Bros. O Background This is a hybrid royalty/debt transaction for $44 million initially entered into on November 2, 2012. PDL acquired from the

Source: SEC EDGAR · 8-K filed Jun 7, 2017

More decks from PDL BioPharma Inc